Related Experiment Video

Updated: Oct 5, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Hepatic lipase gene variation is related to coronary reactivity in healthy young men

Y Fan1, R Laaksonen, T Janatuinen

  • 1Tampere University Hospital and University of Tampere, Medical School, Tampere, Finland.

European Journal of Clinical Investigation
|July 17, 2001
PubMed

Insights

The hepatic lipase (HL) gene C-480T polymorphism is linked to coronary artery function in healthy men. High activity HL genotypes show improved coronary flow reserve (CFR), suggesting a role in early cardiovascular disease development.

Area of Science:

  • Cardiovascular Genetics
  • Molecular Cardiology
  • Vascular Physiology

Background:

  • Impaired coronary flow reserve (CFR) indicates vascular dysfunction preceding angiographic lesions.
  • Hepatic lipase (HL) gene C-480T polymorphism influences HL activity, with controversial links to coronary artery disease.
  • The effect of HL genotypes on coronary function remains unstudied.

Purpose of the Study:

  • To investigate the association between HL genotypes and coronary artery function in healthy young men.
  • To determine if HL gene polymorphism impacts coronary reactivity.

Main Methods:

  • Study included 49 healthy, mildly hypercholesterolemic men (mean age 35 years).
  • Myocardial blood flow assessed using positron emission tomography with [15O] H2O at rest and during hyperemia.
  • HL genotype determined via PCR and Nla III enzyme digestion.

Main Results:

  • No significant difference in resting myocardial blood flow between high and low activity HL genotypes.
  • Coronary flow reserve (CFR) was 24% higher in men with the high activity genotype (n=26) versus low activity (n=23).
  • HL genotype independently predicted CFR in multivariate analysis (P=0.038).

Conclusions:

  • The HL gene C-480T polymorphism may modulate coronary reactivity in healthy young men.
  • This polymorphism could reflect early coronary dysfunction pathogenesis.
  • Further research is needed to confirm if HL polymorphism is a cardiovascular disease risk factor in dyslipoproteinemic populations.
Abstract

More Related Videos

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...